Tersilat is an established medication used to help manage fungal infections that affect the nails and skin. Its clinical purpose provides a benefit in treating onychomycosis (fungal infection of the fingernails and toenails), which often requires systemic therapy. Tersilat supports the body in promoting the natural resolution of these conditions by addressing the fungal organism.

The medication may also be used for certain tinea infections, including athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). For these skin conditions, treatment is intended to promote the healing of affected areas, which leads to improvement in associated symptoms like itching and scaling.

---

Quick Fact: Relief for Itching and Scaling

Regulatory References

1. NIH MedlinePlus guidance

The eligibility for using Tersilat (Topical Terbinafine Hydrochloride) is strictly defined by official government regulatory labeling. This section describes the populations allowed, those prohibited, and those requiring conditional use, based on regulatory criteria.

Populations Prohibited and Restricted

Classification	Eligibility Status	Detail (Regulatory-Based)
Absolute Contraindication	Prohibited	Individuals with known hypersensitivity (allergy) to Terbinafine or any component of the topical formulation.
Pediatric Use	Not Established / Not Recommended	Use is generally restricted to Adults and Adolescents (12 years old). Safety and effectiveness are not established for children under 12.
Pregnancy	Conditional Use	Use is advised only if clearly indicated by a healthcare provider, and when the benefits are determined to outweigh the potential risks.
Lactation	Not Recommended	Use is generally not recommended while breastfeeding due to the potential excretion of the drug into human milk.

Other Eligibility Considerations

Due to the medicine’s minimal systemic absorption when applied topically, official labeling typically mandates no specific restrictions or dose adjustments for patients with pre-existing hepatic (liver) or renal (kidney) impairment. This differs significantly from the restrictions placed on the oral form of the medicine. The official eligibility profile is focused on immune response, age, and physiological state.

Tersilat Interactions with other medicines and products

Interaction Profile Based on Regulatory Documentation

The official interaction profile for Tersilat (Topical Terbinafine Hydrochloride) is consistently defined by its minimal systemic absorption into the bloodstream when applied to the skin. Government regulatory documents typically conclude that, due to the very low exposure, the potential for systemic drug-drug interactions is negligible.

Category	Regulatory Documentation Status
Specific Interacting Medicines	None explicitly listed.
Contraindicated Combinations	None documented due to interaction risk.
Mechanistic Basis (e.g., CYP Enzymes)	None documented for the topical formulation.
Timing or Separation Rules	None documented.
Food, Alcohol, or Supplement Interactions	None documented.

Official Interaction Statements

• No systematic drug interaction studies have been formally performed for the topical cream or solution [FDA, EMA member states].
• No known drug interactions exist between topical terbinafine and other systemic medicinal products [National Regulatory Authorities].
• Mechanistic interactions, such as those related to the CYP450 system (e.g., CYP2D6 inhibition), are associated with the oral formulation only and are not applicable to the topical product.

Connection to the Overall Interaction Profile

The regulatory conclusion across multiple authorities is that the interaction structure is defined by the negligible risk of systemic exposure. This minimal absorption results in an official profile where there are no specific interacting substances, no documented mechanistic basis for interactions, and no formally imposed use restrictions related to co-administering other medicines.

Targeted Inhibition of Fungal Squalene Epoxidase

The mechanism of action centers on the highly specific inhibition of the enzyme squalene epoxidase within the fungal cell. This targeted molecular interference initiates a severe disruption of the fungal ergosterol biosynthesis pathway, which is required for the pathogen's membrane stability and structural integrity.

---

Dual-Mechanism Fungal Cell Death (Fungicidal Action)

Blocking the squalene epoxidase enzyme results in a critical dual effect: a deficiency of ergosterol, which destabilizes the fungal membrane, and the toxic accumulation of the precursor squalene inside the cell. This combined molecular and cellular assault leads directly to the lysis and irreversible death of the fungal organism, an irreversible physiological outcome known as fungicidal activity.

---

Mechanism Specificity and Constraints

The mechanism involves a marked difference in affinity for the fungal enzyme compared to the homologous mammalian enzyme. However, its maximal fungicidal action is specific to dermatophytes; against certain yeasts, the mechanism's outcome is different, producing fungistatic activity (inhibition of growth) rather than rapid cell death.

Tersilat is used for topical administration, applying the medicine directly to the skin surface. The product is available as a 1% cream or solution. For all applications, the affected skin area must be cleansed and dried thoroughly prior to use, after which a thin layer should be applied, covering the lesion and the immediate surrounding skin.

Dosing regimens typically instruct application once daily. However, for specific infections like interdigital athlete’s foot (tinea pedis), the frequency may be twice daily. Treatment duration varies by the specific fungal condition being addressed. Tinea corporis (ringworm) and tinea cruris (jock itch) usually require a course lasting one week, while more resistant forms of tinea pedis may require up to two weeks of consistent application.

The administration is subject to several high-level restrictions. Tersilat is strictly for external use only and must not be applied to the eyes, mouth, or internally. While the dose remains unchanged for older adults, its use in children under 12 years of age is generally not recommended due to limited clinical data. It is observed that irregular use or premature discontinuation of the regimen carries a risk of recurrence, underscoring the importance of completing the full course.

Research Evidence / Overview of Studies for Tersilat

Evidence Base for Treating Common Skin Fungal Infections

The primary research for Tersilat (topical terbinafine) has been conducted using well-structured clinical trials to understand how the medicine was evaluated in research exploring how symptoms change over time in individuals with common skin fungus infections, such as ringworm ( tinea corporis), jock itch ( tinea cruris), and athlete’s foot ( tinea pedis). The main type of research involves Randomized Controlled Trials (RCTs), where people are assigned by chance to receive the terbinafine preparation, an inactive cream (placebo), or sometimes another established treatment. These RCTs provide the foundation for larger reviews, known as Systematic Reviews and Meta-analyses, which combine findings from many separate studies to contribute to the broader evidence landscape.

Research explored the outcomes observed in patients with conditions characterized by episodic or acute manifestations. These studies monitored whether the fungal pathogen could be eliminated from the skin, which researchers call Mycological Cure. They also tracked Clinical Cure, which involved observing the physical clearing of skin signs like redness and rash. Findings describe patterns observed in the studies related to the rate at which fungal clearance was reported, as well as how patients reported their experience with the resolution of symptoms like itching and scaling outcomes related to physical discomfort. Research has explored short-term symptom changes, with data showing patterns related to an observed rate of achieving the study endpoint over defined time intervals.

Core Outcomes Measured in Clinical Trials

Research protocols used in studies exploring short-term symptom changes for this preparation set specific parameters for evaluation. The primary outcomes related to physical discomfort measured included the two-part combined study endpoint: evidence of fungal elimination confirmed by lab tests, and a clinical assessment of symptom resolution. Studies monitored these physiological changes over the short treatment period and for a brief time afterward. Findings describe patterns observed in the studies, which focused on comparing the measurements of these outcomes between the group receiving Tersilat and the groups receiving other treatments or the inactive cream.

---

Durability of Response and Long-Term Research

The majority of evidence derived from settings with varying symptom burdens focuses on the short-term outcomes of the topical preparation. The follow-up durations were limited in many of the key trials. Studies monitored responses typically over a few weeks to a few months after the treatment was completed. This follow-up was designed to observe the persistence of physical and mycological changes after treatment completion.

However, there is limited information for long-term outcomes that would describe if the infection returns or is prevented over extended periods, such as six months or longer. Research highlights what is known—that is, the results apply only to the populations studied under short-term conditions—but long-term effects are not fully established regarding the observation of recurrence over several years.

Key Studies & References

1. Terbinafine Hydrochloride Cream 1% Antifungal Cream (DailyMed Labeling)
2. Fungal infection of the skin (Terbinafine) - WHO Essential Medicines List (EML) Recommendation

Common questions about Tersilat (FAQ)

Q: How quickly should I expect to see the effects of Tersilat?

Clinical trials evaluate the time it takes for the fungal pathogen to be eliminated and for symptoms to fully clear. Studies explored how symptom relief, such as reduced itching, was reported in participants early in the treatment course. Complete resolution of the infection typically requires finishing the full prescribed treatment course.

Q: Can Tersilat interact with common over-the-counter pain relievers?

Official product information indicates that topical Tersilat has minimal systemic absorption when applied to the skin. This means the product is not expected to interact with common over-the-counter pain relievers, such as paracetamol and ibuprofen.

Q: Are there any dietary restrictions or foods I should avoid while using Tersilat?

According to the official product information, there are no known dietary restrictions or specific foods that must be avoided when you are using the topical formulation of Tersilat.

Q: Can I take Tersilat if I am also taking herbal supplements?

Formal studies on interactions between topical Tersilat and specific herbal remedies have not been conducted. Official guidance recommends informing a healthcare provider about all medicines or supplements being used.

Q: Is it OK to drink alcohol while taking Tersilat?

Due to the minimal systemic absorption of the topical cream or solution, alcohol consumption is not formally restricted according to the regulatory documents on the topical formulation.

Q: What is the time frame in which Tersilat's full effect is typically reached?

The full effect, which means the complete cure of the fungal infection, is reached when the entire treatment course is finished. This duration typically lasts between one and two weeks, depending on the specific fungal condition being addressed.

Q: Does Tersilat make you more sensitive to the sun?

Photosensitivity, or an unusual sensitivity to the sun, is a side effect sometimes reported with the oral form of the medicine. While less likely with the topical cream, if such a reaction develops while using the medicine, official regulatory documents mandate the discontinuation of treatment.

Q: What is the recommended storage condition for Tersilat?

Official storage and handling guidelines state that Tersilat should be stored at room temperature, typically between 20 C and 25 C (68 F and 77 F). It is important to keep the medicine in a cool, dry place and away from light to maintain its quality.

Q: Do I need a prescription to get Tersilat?

The active ingredient in Tersilat (topical terbinafine) is available in formulations that are sold both over-the-counter (OTC) and with a doctor's prescription. The requirement depends on the specific product strength and the country where it is purchased.

Q: Will taking Tersilat affect my ability to drive or operate machinery?

Because the topical formulation has minimal absorption into the bloodstream, it is not typically associated with systemic effects, such as drowsiness, that would impair driving. Official documents do not list specific warnings for driving related to the topical product.

Q: What happens if I miss a dose of Tersilat (in general terms)?

Patient information typically indicates that if a dose is missed, it should be applied as soon as it is remembered. The routine application should then continue as scheduled. It is noted that a double dose should not be applied to compensate for the forgotten application.

Q: Is it normal to feel a little dizzy when starting Tersilat?

Dizziness is a side effect that is sometimes reported with the oral form of the medicine, which is absorbed throughout the body. Due to the very minimal absorption of the topical cream into the bloodstream, the likelihood of this side effect is considered low, and it is not listed as a common reaction for the topical product.

Q: Is Tersilat considered a new or older type of medicine?

The active ingredient in Tersilat, terbinafine hydrochloride, is not considered new. It was first granted approval by the U.S. FDA on December 30, 1992, making it an established medicine in the antifungal class.

Q: Can Tersilat be used safely by elderly patients?

Official regulatory documents indicate that the application instructions and dose are unchanged for older adults. Due to its minimal absorption, the topical medicine's regulatory profile does not suggest different side effects or problems in older people compared to younger adults.

Q: Has Tersilat been studied in children or teenagers?

Official safety and effectiveness information has not been established for children younger than 12 years of age, so use is not recommended for this age group. Use in adolescents aged 12 years and older is generally based on the existing adult data.

Q: How long does Tersilat typically stay in the body after stopping?

When applied directly to the skin, the active ingredient in Tersilat can be found localized within the skin layers for several weeks after the use of the medicine has been discontinued. This local persistence is part of its pharmacological profile.

Q: What should I do if I experience a mild skin rash while on Tersilat?

Official guidance indicates that if a rash or any other side effect becomes bothersome, does not go away, or worsens, regulatory mandates suggest discontinuing the medicine and consulting a healthcare professional for further guidance.

Q: Can men and women use Tersilat in the same way?

Yes, for general use, the administration instructions, application frequency, and duration of the treatment course are the same for both men and non-pregnant/non-nursing women.

Q: Is Tersilat a scheduled controlled substance?

No, according to regulatory classification bodies, topical terbinafine is not categorized as a scheduled controlled substance under U.S. DEA or similar international drug scheduling laws.

Q: Are there known interactions between Tersilat and birth control pills?

Topical Tersilat is not believed to interact with the oral contraceptive pill (birth control pills). This is due to its negligible absorption into the bloodstream, which is necessary to cause systemic drug interactions.

Q: Does Tersilat cause stomach upset or digestive issues?

Stomach upset and digestive issues are side effects that are associated with the oral tablet form of the medicine. These are not commonly reported with the topical cream or solution because its action is localized to the skin.

Q: Is Tersilat used to prevent a condition or only to treat it?

The official indications for Tersilat state that it is used for the cure and treatment of fungal infections. Its application is typically reserved for use during an active infection, not for prevention.

Q: How long has Tersilat been available on the market?

The active ingredient, terbinafine hydrochloride, has been available on the market since its initial approval by the U.S. FDA on December 30, 1992, and it is widely recognized internationally.

Q: Can I crush or split the Tersilat tablet?

Tersilat is supplied as a topical cream or solution for external use only. These forms are not tablets intended for crushing or splitting.

To maintain the quality and safety of Tersilat, always store the medication according to the specific temperature, light, and moisture conditions detailed on the prescription drug label or patient information. Keep the medicine in its original, secured container, safely out of reach and sight of children and pets.

For disposal of unused or expired Tersilat, the most preferred method is utilizing a community drug take-back program or a drug mail-back service. If these options are not readily available, and the medicine's label does not specifically instruct flushing, most medications can be disposed of in the household trash. Before discarding, mix the drug with an undesirable substance, such as used coffee grounds or kitty litter, seal the mixture in a container, and remove all personal information from the original packaging to protect privacy.